In a lung cancer patient cohort, both high expression of ADAM17 and PSEN2 were correlated with better first progression survival of patients who underwent systemic therapy while in a breast cancer patient cohort, ADAM17 and PSEN2 expression led to a much narrower gap in relapse-free survival (RFS) of patients who underwent systemic therapy compared to the significantly wide gap in overall survival of patients under the systemically untreated cohort (Supplementary Fig. S10a,b). This evidence concerns the gene PSEN2 and lung cancer.